About
Swipp develops medical orally dissolving films designed for faster drug uptake and simpler administration; its lead product is a buccal midazolam film for treating acute epileptic seizures and has been tested in clinical studies. The company focuses on using established drug substances to shorten development time and aims to reach first clinical trials within about three years.
Explore Swipp's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.